Riders don’t care what kind of system you use. They care that it works and provides what they expect. They expect real-time updates, simple account management, and zero surprises. And public transit ...

The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.

The long-term goal of a fully automated insulin delivery (AID) system that operates without user input to maintain glucose levels within target range remains a future aspiration and may never be fully ...

Smart transit has changed how people move. Riders now expect fast, digital, and contactless experiences. That includes mobile payments, QR tickets, and cashless fare collection. But with all this ...

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With open-loop therapies, insulin administration is manually controlled, while hybrid ...

Please provide your email address to receive an email when new articles are posted on . Pregnant women with type 1 diabetes had a lower time below range with the MiniMed 780 system vs. standard of ...